Genetic Polymorphisms of MRP2 and UGT2B7 and Gastrointestinal Symptoms in Renal Transplant Recipients Taking Mycophenolic Acid

• DOI: 10.1097/ftd.0b013e3181b1dd5e
• Publication Date: 2009-09-22T07:18:02Z
• Authors: Jae Wook Yang; Puay Hoon Lee; Ian V Hutchinson; Vera Pravica; Tariq Shah; David I Min
• Keywords: UGT2B7; Mycophenolate

The aim of this study was to determine the relationship between single nucleotide polymorphisms in multidrug resistance protein 2 (MRP2) and uridine diphosphate glucuronosyltransferase (UGT) 2B7 severity gastrointestinal (GI) symptoms patients receiving mycophenolic acid (MPA). A total 67 renal transplant recipients taking MPA derivatives were included study. Genotypes for MRP2 C-24 T UGT2B7 C802 determined. incidence GI assessed using validated Gastrointestinal Symptom Rating Scale (GSRS) at baseline, weeks, 3 months, 6 months after transplantation. mean overall GSRS score on subscale diarrhea compared Kruskal-Wallis test. scores (23.5 +/- 4.5 vs. 26.7 9.9, P = 0.68) or subscores (3.5 0.9 5.1 3.3, 0.08) not significantly different among with heterozygous variant those homozygous wild type. For UGT2B7, type (CC CT + TT, 29.2 9.3 24.0 8.2, 0.009), although did reach statistical significance 5.7 4.1 1.9, 0.13). When genotypes considered together, forms had lower (CC-CC CT-CT/TT, 22.5 4.3 30.1 10.1, 0.04) 3.4 0.7 6.2 4.4, 0.03). However, there no differences either mofetil (MMF) enteric-coated (EC-MPA) regardless whether calcineurin inhibitors. In conclusion, suggests that MPA, are protected from side effects formulation used concurrent inhibitors administered. show significant therapy.